Thailand Medical Cannabis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Thailand Medical Cannabis Market Segmentation, By Product (Oil, Dried Medical Cannabis, Medical Cannabis Capsules, Vape Pen, Whole Flower, Creams and Moisturiser, Ground Flower, Patch, Mask and Serum, Cleanser, and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer’s Disease/Migraines, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood, and Others), Derivatives (Cannabidiol (CBD), Tetrahydrocannibinol (THC)/Delta-8-Tetrahydrocannabiol, Patch, Cannabigerol (CBG), Cannabinol (CBN), and Others), Source (Natural, and Synthetic), Species (Sativa, Hybrid, and Cannabis Indica), Treatment Type (Expectorant, Antiviral, Analgesic, Aphrodisiac, Psychedelic, and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Topicals, Vaporizers, and Others), End User (Homecare Setting, Hospital, Rehab Centres, Pharmaceutical Industry, Research and Development Centres, and Others), Distribution Channel (B2C, and B2B) - Industry Trends and Forecast to 2032

Thailand Medical Cannabis Market Size

• The  Thailand medical cannabis market size was valued at USD 27.44 billion in 2024 and is expected to reach USD 165.28 billion by 2032, at a CAGR of 25.16% during the forecast period
•  The market growth is largely fueled by the increasing acceptance of medical cannabis for therapeutic use and supportive government initiatives promoting its legalization and integration into mainstream healthcare
•  Furthermore, rising patient demand for natural, plant-based alternatives to synthetic pharmaceuticals is establishing medical cannabis as a preferred treatment option for various chronic conditions

Thailand Medical Cannabis Market Analysis

• Medical cannabis, offering therapeutic potential for a wide range of conditions such as chronic pain, epilepsy, and anxiety, is becoming an increasingly vital component of Thailand’s evolving healthcare and wellness ecosystem, particularly in both clinical and alternative medicine settings due to its expanding regulatory support and integration into traditional Thai medicine
• The escalating demand for medical cannabis in Thailand is primarily driven by progressive legalization, growing public and professional awareness of its health benefits, and the development of a regulated distribution framework
•  Bangkok dominated the Thailand medical cannabis market with the largest revenue share of 34.6% in 2024, attributed to its high concentration of licensed dispensaries, specialized hospitals, and research universities actively participating in cannabis-based clinical research. The capital city’s robust healthcare infrastructure and government-supported pilot clinics have significantly driven prescription volumes and patient access to high-grade medical cannabis
•  Chiang Mai is expected to be the fastest-growing province in the Thailand medical cannabis market during the forecast period, with a projected CAGR of 16.8% from 2025 to 2032, fueled by increasing government support for cannabis cultivation, growth in wellness tourism, and regional emphasis on integrating cannabis with traditional herbal medicine. Chiang Mai’s emergence as a northern hub for cannabis education, certified farms, and practitioner training is driving rapid adoption and market expansion
•  The Oil segment dominated the Thailand Medical Cannabis market with a market share of 28.5% in 2024, driven by its ease of use, precise dosing, and wide applicability in treating chronic conditions such as anxiety, epilepsy, and pain

Report Scope and Thailand Medical Cannabis Market Segmentation

Thailand Medical Cannabis Market Trends

Increasing Demand for Personalized and Natural Therapeutics

• A significant and accelerating trend in the  Thailand medical cannabis market is the rising demand for natural, plant-based therapeutic solutions for managing chronic conditions such as anxiety, epilepsy, cancer-related symptoms, and chronic pain. This shift is creating widespread adoption of medical cannabis across diverse patient demographics
• For instance, in 2024, the Thai government expanded its list of approved cannabis-based therapies for use in state hospitals, including extracts and oil-based medications for palliative care and chemotherapy-related side effects. This governmental support is helping remove social stigma while broadening public access to treatment
• Consumer preference is shifting toward organic and locally produced cannabis products, with dispensaries and health clinics seeing higher demand for full-spectrum oils and capsules derived from locally grown strains. Companies such as Thai Cannabis Corporation are capitalizing on this trend by promoting certified and traceable cannabis sourcing
• The wellness industry in Thailand is also embracing medical cannabis, integrating it into spa services, nutraceuticals, and anti-anxiety remedies. The holistic health movement is further pushing for micro-dosing and tailored dosages through certified professionals, expanding the scope of applications beyond conventional medicine
• In addition, education campaigns by health ministries and private clinics are helping increase public awareness and understanding of safe cannabis usage, thereby reducing hesitancy among older populations and boosting overall patient confidence in cannabis-based therapies
• This growing demand for natural and personalized healthcare solutions is expected to drive robust growth in Thailand's medical cannabis market, especially as regulations continue to evolve to support broader medical use and innovation

Thailand Medical Cannabis Market Dynamics

Driver

Growing Need Due to Rising Demand for Alternative Therapies and Legal Reforms

• The increasing prevalence of chronic illnesses such as cancer, arthritis, anxiety, and neurological conditions, coupled with Thailand’s progressive stance on cannabis regulation, is a significant driver of the heightened demand for medical cannabis
• For instance, in January 2024, Thailand's Ministry of Public Health continued its efforts to expand access to medical cannabis by approving additional cannabis-based treatment centers in public hospitals. Such strategies by key stakeholders are expected to drive the Thailand Medical Cannabis industry growth in the forecast period
• As patients and healthcare providers become more aware of the potential benefits of cannabinoids for symptom management, medical cannabis products offer promising alternatives to traditional pharmaceuticals with fewer side effects, particularly in pain and mental health management
• Furthermore, the growing popularity of natural and holistic treatments and the shift toward personalized medicine are making medical cannabis an integral component of integrative health approaches, offering customized therapeutic outcomes across various disease categories
• The convenience of varied product formats—such as oils, capsules, creams, patches, and vaporizers—alongside the government’s support for controlled distribution and public education, are key factors propelling the adoption of medical cannabis in both clinical and homecare settings. The trend toward self-care, combined with increasing availability of user-friendly Thailand Medical Cannabis options, further contributes to market growth

Restraint/Challenge

Concerns Regarding Regulatory Uncertainty and Limited Clinical Evidence

• Concerns surrounding the inconsistent regulatory framework, coupled with limited large-scale clinical validation, pose significant challenges to broader market penetration in Thailand. Despite legalization for medical purposes, varying interpretations of cannabis-related laws can restrict investor confidence and healthcare provider participation
• For instance, the delay in finalizing Thailand’s Cannabis Act has left some ambiguity regarding commercial production and patient access, causing hesitancy among both prescribers and patients
• Addressing these legal and clinical concerns through transparent policy development, accelerated approval pathways, and expanded research initiatives is crucial for building stakeholder trust. Government bodies, in collaboration with research institutions, are increasingly investing in evidence generation to validate the safety and efficacy of medical cannabis products
• In addition, the relatively high cost of quality-controlled medical cannabis formulations compared to conventional therapies can be a barrier to adoption for price-sensitive consumers, especially in rural areas. While some low-cost CBD products are becoming more accessible, high-purity and standardized pharmaceutical-grade options often carry a premium price
• While prices are expected to normalize with scale and local cultivation, the perceived cost and lack of reimbursement options may continue to hinder widespread adoption
• Overcoming these challenges through regulatory harmonization, physician training, patient education, and investment in local cultivation and processing infrastructure will be vital for sustained growth of the Thailand Medical Cannabis Market

Thailand Medical Cannabis Market Scope

The market is segmented on the basis of product, application, derivatives, source, species, treatment type, route of administration, end user, and distribution channel.

• By Product

On the basis of product, the Thailand medical cannabis market is segmented into oil, dried medical cannabis, medical cannabis capsules, vape pen, whole flower, creams and moisturiser, ground flower, patch, mask and serum, cleanser, and others. The oil segment accounted for the largest market revenue share of 28.5% in 2024, driven by its ease of use, precise dosing, and wide applicability in treating chronic conditions such as anxiety, epilepsy, and pain.

The vape pen segment is expected to witness the fastest CAGR of 20.3% from 2025 to 2032, owing to growing consumer demand for discreet, fast-acting, and portable cannabis consumption methods.

• By Application

On the basis of application, the market is segmented into pain management, anxiety, muscle spasms, nausea, appetite loss, cancer, arthritis, alzheimer’s disease/migraines, epilepsy, depression and sleep disorders, multiple sclerosis, autism, mental health conditions, elevate mood, and others. Pain management dominated the application segment with a market share of 25.1% in 2024, as chronic and cancer-related pain remains a key indication for cannabis prescriptions.

Depression and sleep disorders are expected to grow at the fastest CAGR of 21.6% during the forecast period due to increasing mental health awareness and preference for alternative therapies.

• By Derivatives

On the basis of derivatives, the market is segmented into Cannabidiol (CBD), Tetrahydrocannabinol (THC)/Delta-8-Tetrahydrocannabinol, Patch, Cannabigerol (CBG), Cannabinol (CBN), and others. Cannabidiol (CBD) held the largest market share of 39.7% in 2024, owing to its non-psychoactive nature and widespread use in medical applications.

Cannabigerol (CBG) is projected to expand at the fastest CAGR of 22.9% from 2025 to 2032, due to its potential therapeutic effects in treating glaucoma, inflammatory bowel disease, and neurodegenerative conditions.

• By Source

On the basis of source, the market is segmented into Natural and Synthetic. Natural cannabis dominated with a market share of 76.4% in 2024, driven by strong consumer preference for organic, plant-based therapies.

Synthetic cannabis is is expected to witness the fastest CAGR from 2025 to 2032, particularly in pharmaceutical-grade formulations.

• By Species

On the basis of species, the market is segmented into sativa, hybrid, and cannabis indica. Cannabis Sativa accounted for the largest share at 36.2% in 2024, favored for its energizing effects used in day-time treatments.

Hybrid strains are projected to register the fastest growth from 2025 to 2032, owing to their tailored cannabinoid profiles that offer balanced effects.

• By Treatment Type

On the basis of treatment type, the market is segmented into expectorant, antiviral, analgesic, aphrodisiac, psychedelic, and others. Analgesic treatments held a dominant share of 41.8% in 2024, reflecting strong demand for pain relief applications.

Antiviral are projected to register the fastest growth from 2025 to 2032, owing to their tailored cannabinoid profiles that offer balanced effects.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral solutions and capsules, smoking, topicals, vaporizers, and others. Oral solutions and capsules held the largest market share of 34.5% in 2024, driven by ease of dosing, discretion, and prolonged therapeutic effects.

Topicals are projected to expand at the fastest CAGR of 21.3% from 2025 to 2032, due to increasing demand for localized pain and inflammation relief without systemic side effects.

• By End User

On the basis of end user, the market is segmented into homecare setting, hospital, rehab centres, pharmaceutical industry, research and development centres, and others. Homecare setting accounted for the largest share of 38.9% in 2024, driven by the rising prevalence of chronic pain and mental health conditions treated at home.

Pharmaceutical industry is expected to witness the fastest CAGR from 2025 to 2032, as companies intensify efforts in cannabinoid-based drug development and clinical research.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into B2C and B2B. B2C dominated the market with a share of 61.7% in 2024, supported by growing availability of cannabis products through dispensaries, online platforms, and wellness retail chains.

B2B is projected to grow at the fastest CAGR of 20.4% from 2025 to 2032, driven by rising partnerships, white-label manufacturing, and bulk procurement by pharmaceutical and cosmetic companies.

Thailand Medical Cannabis Market Regional Analysis

• Thailand accounted for 13.4% share in the Asia-Pacific in medical cannabis market in 2024, driven by progressive legalization policies, robust government support, and rising patient awareness. As the first Asian country to legalize medical cannabis, Thailand has rapidly built a regulated ecosystem supporting cultivation, distribution, and clinical use
• Consumer demand is growing across both urban and rural areas due to increasing acceptance of cannabis-based therapies for chronic pain, insomnia, anxiety, and cancer-related symptoms. The expansion of certified cannabis clinics, wellness centers, and pharmacies offering medical cannabis has contributed to strong market penetration
• Support from the Thai government—through initiatives like GPO-led cannabis production, local cultivation permits, and the integration of cannabis into traditional Thai medicine—continues to fuel growth. In addition, medical tourism related to cannabis-based treatments is gaining popularity, particularly in wellness-centric provinces

Thailand Medical Cannabis Market Share

The Thailand medical cannabis industry is primarily led by well-established companies, including:

• Tilray (U.S.)
• Elixinol (Australia)
• Extractas (Australia)
• BOL Pharma (Israel)
• PharmaHemp (Slovenia)
• Kiehl’s Since 1851 (U.S.)
• Canopy Growth Corporation (Canada)
• Cresco Labs (U.S.)

Latest Developments in Thailand Medical Cannabis Market

• In March 2022, Aurora Cannabis Inc. acquired Terra Farma Inc., bolstering its Canadian and Europe’s market presence. The integration of Terra Farma's Thrive team into Aurora's portfolio aims to enhance its Canadian recreational offerings, focusing on premium cannabis products such as dried flowers, pre-rolls, vapor products, and concentrates
• In January 2021, Canopy Growth Corporation launched nine retail franchised cannabis outlets across Ontario, aiming to meet rising consumer demands and boost sales. This expansion reflects the company's strategic efforts to capture market opportunities and strengthen its retail footprint

SKU-64237